Abstract
There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Current Radiopharmaceuticals
Title: Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Volume: 2 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Abstract: There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030214
DOI https://dx.doi.org/10.2174/1874471010902030214 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Aspects of Stromal-Parenchymal Interactions in Malignant Neoplasms
Current Molecular Medicine Some Wild-Growing Plant Species from Serbia and Montenegro as the Potential Sources of Drugs
Current Pharmaceutical Design Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Chlorophylls and their Derivatives Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Nanoparticles of Biodegradable Polymers for Clinical Administration of Paclitaxel
Current Medicinal Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of Human Melanoma Cell Replication Using Protein Transduction Technology with a Uracil-DNA Glycosylase Inhibitor
Letters in Drug Design & Discovery Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Maternal Fish Oil Supplementation: The Prodrom of Synaptic Protection in Alzheimers Disease
Current Nutrition & Food Science The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Reviews on Recent Clinical Trials Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine